1 Clinical Efficacy and Serum Inflammatory Factor Level (serum IFCs, bone Gla protein (BGP), and bone turnover markers β-collagen degradation product (β-CTX), and procollagen type 1 N-terminal propeptide (P1NP) )Changes of Zoledronic Acid and Denosumab in T
serum IFCs, bone Gla protein (BGP), and bone turnover markers β-collagen degradation product (β-CTX), and procollagen type 1 N-terminal propeptide (P1NP) )
Abstract
Introduction: postmenopausal osteoporosis (PMOP) is a common bone disorder. Zoledronic acid and denosumab are widely utilized in the treatment of osteoporosis. This work aimed to explore the clinical effects and changes in serum inflammatory cytokine (IFC) levels of zoledronic acid and denosumab in the therapy of PMOP.Materials and Methods: eighty PMOP patients who visited our hospital from March 2021 to March 2024 were recruited and rolled into a control group (CG, n=40) and a treatment group (TG, n=40). CG received zoledronic acid plus traditional treatment, while TG received zoledronic acid plus denosumab plus traditional treatment. Clinical symptom improvement and changes in bone mineral density (BMD) were recorded and compared between the two groups. Changes in serum IFC levels were measured.Results: relative to CG, patients in TG showed greatly increased BMD (P<0.05), and markedly decreased levels of serum IFCs, bone Gla protein (BGP), and bone turnover markers β-collagen degradation product (β-CTX), and procollagen type 1 N-terminal propeptide (P1NP) (P<0.05). Additionally, the incidence of adverse reactions was drastically lower (P<0.05) in TG, and the total effective rate of clinical treatment was notably higher (P<0.05).Conclusion: zoledronic acid combined with denosumab demonstrates good clinical efficacy in PMOP patients, improving clinical symptoms and promoting increased BMD. Furthermore, this combined treatment regimen can reduce serum IFC levels, possibly promoting the treatment of osteoporosis by suppressing inflammatory responses.
References
Adami, G., Pedrollo, E., Rossini, M., Fassio, A., Braga, V., Pasetto, E., Pollastri, F., Benini, C., Viapiana, O. and Gatti, D., 2024. Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study. JBMR Plus, 8(4): ziae016. https://doi.org/10.1093/jbmrpl/ziae016
Crack, L.E., Haider, I.T., Simonian, N., Barroso, J., Gabel, L., Schnitzer, T.J. and Edwards, W.B., 2023. Zoledronic acid after spinal cord injury mitigates losses in proximal femoral strength independent of ambulation ability. Osteoporos. Int., 34(9): 1637-1645. https://doi.org/10.1007/s00198-023-06811-w
Deardorff, W.J., Cenzer, I., Nguyen, B. and Lee, S.J., 2022. Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: a meta-analysis of randomized clinical trials. JAMA Intern. Med., 182(1): 33-41. https://doi.org/10.1001/jamainternmed.2021.6745
Dhangar, S., Shanmukhaiah, C., Sawant, L., Ghatanatti, J., Shah, A., Mathan, S.L.P. and Vundinti, B.R., 2023. Synergetic effect of azacitidine and sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement. Cancer Genet., 274-275: 26-29. https://doi.org/10.1016/j.cancergen.2023.03.004
Gazoni, F.M., Civile, V.T., Atallah, Á.N., Santos, F.C. and Trevisani, V.F.M., 2023. Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis. Sao Paulo Med. J., 141(6): e2022480. https://doi.org/10.1590/1516-3180.2022.0480.R1.27032023
GBD Chronic Respiratory Disease Collaborators, 2020. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir. Med., 8(6): 585-596. https://doi.org/10.1016/S2213-2600(20)30105-3
Ho, W.C., Chang, C.C., Wu, W.T., Lee, R.P., Yao, T.K., Peng, C.H. and Yeh, K.T., 2024. Effect of osteoporosis treatments on osteoarthritis progression in postmenopausal women: a review of the literature. Curr. Rheumatol. Rep., 26(5): 188-195. https://doi.org/10.1007/s11926-024-01139-8
Hu, Q., Wang, Q., Liu, F., Yao, L., Zhang, L. and Chen, G., 2022. Combination of calcitriol and zoledronic acid on PINP and β-CTX in postoperative patients with diabetic osteoporosis: a randomized controlled trial. Dis. Markers, 2022: 6053410. https://doi.org/10.1155/2022/6053410
Huang, X., Ni, B., Li, Q., Liu, M., Zhao, M., Zhang, Y., Shi, X. and Wang, W., 2024. Association between postmenopausal osteoporosis and IL-6, TNF-α: a systematic review and a meta-analysis. Comb. Chem. High Throughput Screen. https://doi.org/10.2174/0113862073262645231121025911
Jiacong, H., Qirui, Y., Haonan, L., Yichang, S., Yan, C. and Keng, C., 2023. Zoledronic acid induces ferroptosis by upregulating POR in osteosarcoma. Med. Oncol., 40(5): 141. https://doi.org/10.1007/s12032-023-01988-w
Lei, M., Zhu, Z., Hu, X., Wu, D., Huang, W., Zhang, Y. and Chen, H., 2024. Postoperative antiosteoporotic treatment with zoledronic acid improves rotator cuff healing but does not improve outcomes in female patients with postmenopausal osteoporosis: a prospective, single-blinded, randomized study. Arthroscopy, 40(3): 714-722. https://doi.org/10.1016/j.arthro.2023.09.033
Li, W., Ning, Z., Yang, Z., Fan, T., Yao, M., Zhang, W., Wang, M., Wen, A. and Wang, J., 2022. Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies. Arch. Osteoporos, 17(1): 84. https://doi.org/10.1007/s11657-022-01129-2
Liu, H., Xiong, Y., Zhu, X., Gao, H., Yin, S., Wang, J., Chen, G., Wang, C., Xiang, L., Wang, P., Fang, J., Zhang, R. and Yang, L., 2017. Icariin improves osteoporosis, inhibits the expression of PPARγ, C/EBPα, FABP4 mRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized rats. Exp. Ther. Med., 13(4): 1360-1368. https://doi.org/10.3892/etm.2017.4128
Liu, H., Zhao, A., Huang, Y., Hou, A., Miao, W., Hong, L., Deng, N. and Fan, Y., 2022. Efficacy and mechanisms of oleuropein in postmenopausal osteoporosis. Comput. Math. Methods Med, 2022: 9767113. https://doi.org/10.1155/2022/9767113
Liu, X., Liu, H., Xiong, Y., Yang, L., Wang, C., Zhang, R. and Zhu, X., 2018. Postmenopausal osteoporosis is associated with the regulation of SP, CGRP, VIP, and NPY. Biomed. Pharmacother., 104: 742-750. https://doi.org/10.1016/j.biopha.2018.04.044
Meng, S., Tong, M., Yu, Y., Cao, Y., Tang, B., Shi, X. and Liu, K., 2023. The prevalence of osteoporotic fractures in the elderly in China: a systematic review and meta-analysis. J. Orthop. Surg. Res., 18(1):536. https://doi.org/10.1186/s13018-023-04030-x
Qaseem, A., Hicks, L.A., Etxeandia-Ikobaltzeta, I., Shamliyan, T., Cooney, T.G.; Clinical Guidelines Committee of the American College of Physicians; Cross, J.T. Jr, Fitterman, N., Lin, J.S., Maroto, M., Obley, A.J., Tice, J.A. and Tufte, J.E., 2023. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the american college of physicians. Ann. Intern. Med., 176(2):224-238. https://doi.org/10.7326/M22-1034
Sun, W., Xing, Y., Zhou, F., Ma, Y., Wan, X., and Ma, H., 2023. Association analysis of triglyceride glucose-body mass index and bone turnover markers in patients with type 2 diabetes mellitus. Diabetes Metab. Syndr. Obes., 16: 1435-1447. https://doi.org/10.2147/DMSO.S406849
Valadares, L.P., de Araújo Ferreira, B.S., da Cunha, B.M., Moreira, L.A., Batista, F.G.A., da Fonseca Hottz, C. and Magalhães, G.G.R., 2022. Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience. Arch. Endocrinol. Metab., 66(2): 247-255. https://doi.org/10.20945/2359-3997000000459
Viswanathan, M., Reddy, S., Berkman, N., Cullen, K., Middleton, J.C., Nicholson, W.K. and Kahwati, L.C., 2018. Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US preventive services task force. JAMA, 319(24): 2532-2551. https://doi.org/10.1001/jama.2018.6537
Wang, W.Y., Chen, L.H., Ma, W.J. and You, R.X., 2023. Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials. Eur. Rev. Med. Pharmacol. Sci., 27(17): 8253-8268. https://doi.org/10.26355/eurrev_202309_33586
Zhang, X., Wang, Z., Zhang, D., Ye, D., Zhou, Y., Qin, J. and Zhang, Y., 2023. The prevalence and treatment rate trends of osteoporosis in postmenopausal women. PLoS One, 18(9): e0290289. https://doi.org/10.1371/journal.pone.0290289
Zhang, Y., Huang, X., Sun, K., Li, M., Wang, X., Han, T., Shen, H., Qi, B., Xie, Y. and Wei, X., 2022. The potential role of serum IGF-1 and leptin as biomarkers: towards screening for and diagnosing postmenopausal osteoporosis. J. Inflamm. Res., 15: 533-543. https://doi.org/10.2147/JIR.S344009
Zhou, W., Zhang, W., Yan, S., Zhang, K., Wu, H., Chen, H., Shi, M., Zhou, T., 2024. Novel therapeutic targets on the horizon: an analysis of clinical trials on therapies for bone metastasis in prostate cancer. Cancers (Basel), 16(3): 627. https://doi.org/10.3390/cancers16030627
Copyright (c) 2025 Jun Ma
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.